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Sepsis-induced multiple organ failure (MOF) is the most frequent lethal disease in intensive care units. Thus, it is important
to elucidate the self-defensive mechanisms of sepsis-induced MOF. Hepatocyte growth factor (HGF) is now recognized as
an organotrophic factor, which is essential for organogenesis during embryonic growth and regeneration in adulthood. HGF
productionisenhancedinresponsetoinfectiouschallenges,buttheincreaseinendogenousHGFlevelsistransientandinsuﬃcient,
with a time lag between tissue injuries and HGF upregulation, during progression of septic MOF. Thus, administration of active-
formed HGF might be a new candidate for therapeutic development of MOF. HGF has an ability to target endotoxin-challenged
macrophages and inhibits the upregulation of inﬂammatory cytokines through nuclear factor-κB-inactivated mechanisms. HGF
also targets the endothelium and epithelium of various organs to suppress local inﬂammation, coagulation, and apoptotic death.
ThispapersummarizesthenovelmechanismsofHGFforattenuatingsepsis-relatedpathologicalconditionswithafocusonsepsis-
induced MOF.
1.Introduction
In the ﬁrst 10 years of the 21st century, the prevalence of
sepsisincreasedworldwideduetoanemergenceofinfectious
disorders. Multiple organ failure (MOF) often occurs and
progresses during septic pathological conditions such as
hypercoagulation and inﬂammation [1]. In particular, sys-
temic inﬂammatory response syndrome (SIRS) is a clinical
feature of a generalized inﬂammatory reaction in organs
that are distant from the initiating insult [2]. Approximately,
700,000 hospitalized patients develop sepsis each year in the
United States, resulting in more than 210,000 deaths; this
number accounts for 10% of all deaths annually and exceeds
the number of deaths due to myocardial infarction [3].
Importantly, acute renal failure (ARF) and acute respiratory
distress syndrome (ARDS) play a signiﬁcant role in the
setting of MOF during severe sepsis [3, 4]. Moreover, hepatic
injury sometimes occurs as a consequence of continuous
infection or shock, systemic and local inﬂammation, and
hypoxia [5].
From the viewpoint of pathogenesis, SIRS is inducible
by immune cells, especially by activated macrophages, via an
innateimmunemechanism.Forexample,lipopolysaccharide
(LPS) is localized in the outer membranes of Gram-negative
bacteria and acts as endotoxins to elicit strong immune
responses in the host via binding to Toll-like receptor 4
(TLR4) that is expressed mainly on macrophages [6]. The
binding of LPS to its receptor, TLR4, provokes transductions
of intracellular signaling leading to an activation of nuclear
factor (NF)-κB, a key transcriptional factor for triggering
inﬂammation, and then proinﬂammatory cytokines, such
as tumor necrosis factor-α (TNF-α) and interleukin (IL-)1,
6, and 18, are released from macrophages to blood. Under
such a systemic inﬂammatory condition, MOF-related lethal2 Gastroenterology Research and Practice
events become evident not only in macrophages (i.e., an
initial step for cytokine storm) but also in vessels (i.e., an
early step for edema and thrombosis) and organ tissues (i.e.,
an advanced step for apoptosis, necrosis, and loss of func-
tion). These pathological circuits are required to establish
MOF-related conditions [3–5]. Thus, several approaches to
intercept the MOF-related circuits may be useful for the
improvement in septic mortality.
Hepatocyte growth factor (HGF) was originally identi-
ﬁed and cloned as a potent mitogen for hepatocytes [7–9].
HGF acts on various types of cells through its receptor, c-
Met,andexhibitspleiotropicactivitiesduringembryogenesis
and tissue repair [10–15]. For instance, HGF protects the
parenchyma by stimulation of hepatocyte proliferation and
inhibition of functional cell loss during liver injury [14, 15].
Indeed, endogenous and exogenous HGF prevents acute
hepatic failure in rodents, associated with the anti-apoptotic
and anti-necrotic eﬀect of HGF on hepatocytes [10, 15].
During sepsis, plasma HGF levels gradually increase in septic
patients[16],whilemacrophagesacquirehighlevelsofc-Met
in vitro and in vivo (animal models) [17–20]. Recent reports
delineated the novel anti-inﬂammatory eﬀects of HGF on
various types of cells, including macrophages. Of interest,
LPS challenge increased not only TLR4 expression but also
HGF and c-Met production both in vitro [17, 18]a n din
vivo (animal models) [19, 20], thereby suggesting a possible
physiological eﬀect of HGF on LPS-TLR4 signaling. The
present paper focuses on both the emerging roles of HGF in
sepsis and the therapeutic potential of HGF-c-Met signaling
to prevent or reverse MOF-related pathological conditions.
2. Biological Activityof HGFthrough
Its Receptor, c-Met
In the mid- to late-1980s, HGF was identiﬁed and cloned as
a mitogen in the primary culture of rat hepatocytes [7–9].
On the other hand, c-Met, a proto-oncogene product, was
identiﬁedasahighaﬃnityreceptorspeciﬁcforHGF[21,22].
Binding of HGF to c-Met induces activation of tyrosine
kinase, which results in biological activities on a wide variety
of cells, including mitogenic, motogenic, and morphogenic
activities (Figure 1). In addition to these regenerative eﬀects,
anti-apoptotic and anti-inﬂammatory roles of HGF have
been widely demonstrated in vitro and in vivo,a sd e s c r i b e d
below.
2.1. Anti-Apoptotic Eﬀects. Apoptosis is an important event
in the loss of parenchymal components, and Fas signaling
is involved in this process. Of note, HGF inhibits Fas-
mediated apoptosis [23, 24]. Treatment of primary cultured
hepatocyteswithaspeciﬁcFasagonist(Jo-2)rapidlyinduced
apoptosis via a caspase-3-activated pathway. In contrast,
HGF strongly inhibited the caspase-3 activation induced
by Jo-2 in mouse hepatocytes via the induction of anti-
apoptotic molecules such as Bcl-xL [23]. Likewise, HGF
induces the expression of myeloid cell leukemia-1 (Mcl-1),
which is another member of the Bcl-2 family proteins in
hepatocytes [25]. In addition, FLICE-like inhibitory protein
(FLIP) negatively regulates the Fas signaling pathway by
interfering with activation of caspase-8. Upon activation of
Fas, FLIP is rapidly degraded via the proteasome pathway,
whereas HGF prevents degradation of FLIP in a PI3K/Akt-
dependent pathway [26]. Such anti-apoptotic eﬀects of HGF
contribute to organ protection, especially after the onset of
cytokine storm, as discussed later (see Section 4).
2.2. Anti-Inﬂammatory Functions. One of the most key
results related to novel functions of HGF during sepsis is that
HGF directly targets immune cells, including macrophages
and lymphocytes that highly express HGF-receptor, c-
Met, under inﬂammatory conditions. Such direct anti-
inﬂammatory eﬀects of HGF are considered to be the key
mechanism whereby HGF inhibits cytokine storm in an
initialstageofsepsis.Inthissection,wesummarizebiological
activities of HGF, which are required for inhibiting the
progression of SIRS-related pathological conditions.
Macrophages. There is now ample evidence that macro-
phages acquire c-Met after LPS challenge in vitro and in
vivo [17–20]. Furthermore, sepsis-mediated thrombosis and
hypoxia also enhance c-Met expression by macrophages
through upregulating hypoxia-inducible factor-1 (HIF-1),
a transcription factor for transcription of c-Met mRNA
[27]. HGF produces several eﬀects on macrophages. The
most highlighted ﬁnding is that HGF inhibits LPS-mediated
production of proinﬂammatory cytokines, such as TNF-α,
IL-1β, IL-6, and IL-18 [28, 29]. Moreover, HGF induces
macrophage diﬀerentiation with an anti-inﬂammatory phe-
notype (type-M2), rather than with a proinﬂammatory phe-
notype (type-M1) [30]. These eﬀects lead to a minimization
of MOF, as discussed later (see Sections 4 and 5).
Endothelium. Under septic conditions, neutrophils play a
key role for tissue destruction via release of apoptotic
enzymes, such as elastase. During the process of neutrophil
inﬁltration, vascular endothelial cells provide an important
anchorage (such as ICAM-1 and E-selectin) for neutrophil
adhesion on endothelial cell surfaces, resulting in rolling and
extravasation [31]. Using a mouse model of renal ischemia,
we ﬁrst provided evidence that HGF suppresses the neu-
trophil extravasation via inhibiting TNF-α-induced ICAM-
1 expression on endothelium (e.g., HUVEC model) [32].
These results were also reproducible in other models, where
HGF counteracted the endothelial E-selectin expression and
this eﬀect attenuated chronic kidney injury in rodents [33,
34]. Thus, HGF-mediated inhibition of neutrophil-adherent
molecules (such as ICAM-1/E-selectin) is contributable for
reducingneutrophilinﬁltrationandsubsequentattackunder
inﬂammatory states, especially at an early phase of MOF, as
discussed later.
2.3. Anti-Coagulant Properties. In addition to inﬂammatory
phenomena, disseminated intravascular coagulation (DIC)
is a common event under septic conditions. Interestingly,
thrombosis increases blood HGF levels by degranulation of
mast cells [35], suggesting a possible physiological eﬀectGastroenterology Research and Practice 3
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Figure 1:ProductionandmultifacetedfunctionsofHGF.(a)Production,activation,anddeliveryofHGF.HGFisproducedinmesenchymal
cells such as ﬁbroblasts. HGF is secreted in an inactive form (i.e., pro-HGF). Under injurious conditions, pro-HGF is converted to mature
HGFbyHGF-convertingenzymes,suchasuPA.HGFisdeliveredtoinjuredsitesviaendocrineandparacrinepathways[10].(b)Multifaceted
biologicalactionsofHGF,mediatedviac-Mettyrosinephosphorylation,areoutlined.Inductionofmitogenic,motogenic,andmorphogenic
(3M) eﬀects of HGF are essential for organ development and regeneration. Anti-apoptotic eﬀects are required for protection against various
types of organ injuries.
of HGF against DIC. Actually, HGF elicits anti-coagulant
outcomes in several types of liver diseases [36, 37], possi-
bly through the induction of urokinase-type plasminogen
activator (uPA) that is known to stimulate ﬁbrinolysis [38].
Furthermore, HGF is shown to inhibit edematous formation
postthrombosis via Rac-dependent inhibition of the Rho
pathway [39]. These eﬀects lead to the reduction of ﬁbrin
deposition in endothelial lumens under pathological states
[28, 37]. IL-6 is responsible for thrombosis during sepsis,
while HGF potently inhibits IL-6 production in LPS-primed
macrophages [28]. Thus, these direct and indirect eﬀects by
c-Met signaling lead to anti-coagulant outcomes in rodents
withsepsis.ThecellstargetedbyHGFanditsfunctionduring
inﬂammation and coagulation are summarized in Table 1.
3. Regulation andSigniﬁcance of
HGFProductionduringSepsis
Several lines of clinical studies demonstrated that blood and
localHGFlevelsincreasedinpatientswithinfectiousdiseases
with septic features [16, 47, 48]. Under inﬂammation, HGF
is produced and delivered to injured tissue via systemic
(i.e., endocrine) and local (i.e., paracrine) mechanisms [10,
15]. Sepsis-mediated upregulation of HGF is suggested to
be an eﬀort to minimize the manifestation of MOF, but
this response may be transient, delayed and sometimes
insuﬃcient, during progression of septic MOF. Prior to
discussion on the therapeutic value of HGF, we emphasize
the possible role of endocrine and paracrine pathways in
HGF production, because this response may lead to the
elicitation of defensive responses to injury.
3.1. Production and Delivery of HGF during Sepsis
(A) Endocrine System. Under a healthy state, HGF is pro-
duced at a physiological level (0.2–0.4ng/mL in blood)
by mesenchymal cells to sustain parenchymal homeostasis,
and this production is enhanced in a response to tissue
injury [11]. Of interest, bacterial components, such as LPS
from Gram-negative bacteria, protein A from Staphylococcus
aureus, and ﬁmbriae of Porphyromonas gingivalis stimulates
HGF production in ﬁbroblasts or macrophages through
a transcriptional pathway [18, 49, 50]. Blood-born HGF
can be stocked on surface of neutrophils, while LPS or
TNF-α releases HGF from the cell surface (i.e., detachment4 Gastroenterology Research and Practice
Table 1: Biological eﬀects of HGF on target cells, involved in sepsis-related MOF.
Target cells Eﬀect Involved mechanism References
Epithelial cells
Mitogenesis Grab2-MAPK [13]
Migration Gab1-PI3K [13]
Morphogen Gab1-PI3K [13]
Anti-apoptosis Bcl-xL induction [15, 40]
Vascular cells
Endothelium Mitogenesis MAP-kinase [10]
Anti-inﬂammation Anti-NF-κB[ 32, 41–43]
Anti-apoptosis Bcl-2 upregulation [10]
Anti-coagulation TM preservation [44, 45]
Pericytes Anti-proliferation Anti-MAPK [10, 15]
Immune cells
Macrophages Anti-cytokine storm HO-1 upregulation [28, 29]
Anti-NFκB activation GSK3β de-phosphorylation [46]
DC Tolerogenic eﬀects TH1   TH2 balance [10, 30]
Eosinophils Anti-inﬂammation Inhibition of eosinophilic toxin release [10]
T-lymphocytes Anti-proliferation IFN-γ downregulation [10]
Epithelial cells include hepatocytes, renal tubular cells, and alveolar and bronchial epithelium. TM: thrombomodulin; DC: dendritic cells; GSK3β:g l y c o g e n
synthase kinase-3β. For abbreviations see text or original references.
mechanism) [51]. These transcriptional and nontranscrip-
tional mechanisms couldcontributetoanendocrine delivery
of HGF to injured tissues through vascular blood ﬂow.
(B) Paracrine System. In addition, the paracrine system of
HGF delivery production is also important as a local defen-
sive system. Under infectious diseases, neutrophils undergo
apoptosis after intake of bacteria and then are phagocytized
by inﬁltrated macrophages. During this process, HGF tran-
scription is enhanced in activated macrophages [52]a n dde
novosynthesizedHGFisdeliveredtoneighboringepithelium
via a paracrine loop. LPS is known to induce inﬂam-
matory cytokines, such as TNF-α, IL-1, and IL-6 via the
TLR4-dependent pathway, and interestingly, these cytokines
enhance HGF production in mesenchymal cells [53, 54].
Such an inﬂammation-dependent upregulation of HGF
may also participate in paracrine (and possibly, endocrine)
mechanisms for inducing self-defense responses [10, 15].
3.2. A Protective Role of Endogenous HGF-c-Met Axis during
Sepsis. LPS stimulates the production of not only ligand
HGF but also its receptor, c-Met [17]. Furthermore, LPS
promotes the mitogenic eﬀects of HGF in various organs
in rats [55], suggesting that LPS also elicits compensatory
responses, in contrast to the primary function (i.e., a
trigger of the innate immune system). Indeed, blood HGF
levels are elevated in septic mice, in association with
concomitantincreasesofphosphorylatedc-Metsignalsinthe
macrophages and renal cells [28, 29, 56]. Of note, anti-HGF
IgG worsens tissue injuries in LPS-treated mice, thus sug-
gesting that endotoxin-induced increases in HGF and c-Met
are required for reducing organ destruction and dysfunction
against septic stresses in animals (and possibly in humans).
3.3. HGF as a Diagnostic Marker of SIRS-to-MOF. Since
endogenous HGF is important for driving self-defensive
system, local or systemic HGF may be useful for diagnosis of
septic conditions: HGF levels signiﬁcantly increase in blood
or bronchoalveolar lavage ﬂuids (BALFs) of patients during
infectious diseases [11, 57]. For example, HGF is detected
exclusively in BALF from patients with sepsis-related acute
respiratory distress syndrome (ARDS), and the elevation
in HGF levels is evident in patients with severe, rather
than mild, injury [57]. Given that HGF is protective during
sepsis, the increase of blood HGF may be interpreted as
a compensated response, rather than a risk factor. Blood
HGF is now suggested to be a sensitive marker to predict
the severity of tissue injuries under clinical situations (see
Table 2).
Duringthepast20years,wehavepostulatedthatendoge-
nous HGF is a key physiological regulator to minimize organ
damage and dysfunction in various organs [10, 15]. In a
rat model of sepsis, enhancement of HGF production was
insuﬃcient,withatimelag,afteranendotoxicchallenge(i.e.,
3-fold increase at 12 hours after LPS treatment), associated
with the onset of septic hepatitis [63]. Based on this
background, we demonstrated in the late 1990s that a forced
increase by supplemental therapy with HGF could prevent
LPS-induced hepatitis [40]. This concept is now widely
supported in rodent models of septic diseases, as follows.
4. Therapeutic Effects of HGF on
MOF duringSepsis
Sepsis-induced MOF is the most frequent disease in the
intensive care unit (ICU). In the United States, an estimatedGastroenterology Research and Practice 5
Table 2: Increases in blood HGF levels in patients during various diseases.
Patients (P) Healthy control (HC) Ratio of P to HC (Fold increase) Literature
Sepsis
0.69 ± 0.47ng/mL∗ 0.10 ± 0.03ng/mL 6.90 Sakon et al. [47]
SIRS (non-sepsis)
0.49 ± 0.37ng/mL 0.10 ± 0.03ng/mL 4.90 Sakon et al. [47]
Septicemia
4.53–5.11ng/mL∗∗ 0.7–0.77ng/mL approx. 6.5 Nayeri et al. [48]
Skin infection
2.61–2.75ng/mL 0.7–0.77ng/mL approx. 3.7 Nayeri et al. [48]
Bacterial pneumonia
0.96 ± 0.27ng/mL 0.29 ± 0.03ng/mL 4.18 Maeda et al. [58]
Acute hepatitis
0.45 ± 0.23ng/mL 0.27 ± 0.08ng/mL 1.67 Shiota et al. [59]
Chronic hepatitis
0.40 ± 0.16ng/mL 0.27 ± 0.08ng/mL 1.48 Shiota et al. [59]
Liver cirrhosis
1.05 ± 0.64ng/mL 0.27 ± 0.08ng/mL 3.89 Shiota et al. [59]
Severe pancreatitis
2.30 ± 0.61ng/mL n.d. n.d. Ueda et al. [60]
Ulcerative colitis
1.38 ± 0.11ng/mL n.d. n.d. Srivastava et al. [61]
∗Average value ± SD, ∗∗Median-mean value, and n.d.: not done.
During organ injury, endogenous HGF is delivered through endocrine and paracrine pathways and contributes to an increase in blood HGF levels [10].
HGF seems to be present in blood in an inactive form (i.e., pro-HGF) [62]. Thus, a rapid administration of recombinant HGF (i.e., active HGF) may be
recommended under pathological conditions. Pharmacological levels of recombinant HGF in blood can be sustained within a range of 3–30ng/mL, by
modifying the injection doses and their intervals [15, 32].
700,000 cases of sepsis occur annually [3], resulting in
210,000 deaths; this number accounts for 10% of all deaths
annually and exceeds the number of deaths due to myocar-
dial infarction [3]. Nevertheless, there are no treatments
speciﬁc to septic organ injury. We and other groups have
accumulated evidence to show that HGF, an intrinsic anti-
inﬂammatory regulator, is useful to inhibit or reverse sepsis-
induced hepatitis, ARDS, and acute renal failure (ARF) at
least in animal models, as described below.
4.1. Anti-Apoptotic and Anti-Coagulant Outcomes of HGF
during Hepatitis. LPS elicits intravascular thrombosis and a
localdecreaseinbloodﬂow,andthenparenchymalapoptosis
becomes evident under such a hypoxic condition. Using
LPS- and D-galactosamine (GalN-) treated mice as a “lethal”
model of sepsis, we found that an early induction of anti-
apoptotic molecule (such as Bcl-xL) by recombinant HGF
leads to the inhibition of massive hepatocyte loss and hepatic
dysfunction [40]. In this process, exogenous HGF strongly
blocked mitochondrial damages and caspase-3 activation
induced by LPS + GalN. As a result, 75% of septic mice
were rescued by the HGF injections, while all control mice
died of severe hepatic failure within 8 hours after septic
challenge without HGF treatment [40]. Based on these data,
we emphasized that HGF may have the potential to inhibit
fulminant hepatic failure during sepsis via its potent anti-
apoptotic action.
Considering that HGF stimulates ﬁbrinolysis [38], HGF
may improve thrombosis. With regard to this, Seto et al.
investigated the protective eﬀect of HGF on sinusoidal
endothelial cells (SECs) in the LPS-induced liver injury of
rats [44]. Indeed, ﬁbrin was deposited mainly in SEC in
the LPS-treated rats. In contrast, ﬁbrin deposition by SEC
becamemildwhenHGFwassupplementedviasplenictrans-
plantationofHGF-producingﬁbroblastsinendotoxemicrats
[44], indicating an anti-thrombotic eﬀect of HGF under
septic conditions. Interestingly, thrombosis itself induces
a rapid increase of HGF in blood through the release
of mast cell granulations (including heparin) by throm-
bin stimulation [35]. Such a circuit between thrombosis
and HGF upproduction is thought to be a counteractive
response to arrest the progression of thrombosis. Thus, early
administration of recombinant HGF may be one of new
candidates for therapeutic development of DIC during septic
conditions.
4.2. Prevention of ARDS by HGF Treatment. The lung is
one of the most frequently identiﬁed organs to fail in sepsis
and is also the most frequent primary site of infection
[4]. The development of ARDS is common in those cases.
ARDS is caused by protein-rich pulmonary edema that
elicits severe hypoxemia. The lung injury is caused by
primarily neutrophil- and platelet-dependent damage to
the endothelial and epithelial barriers of the lung under6 Gastroenterology Research and Practice
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Figure 2: Therapeutic eﬀects of recombinant HGF on MOF induced by LPS in mice. (a) Inhibitory eﬀect of HGF treatment on cytokine
storm. LPS-induced increases in plasma IL-1β, IL-6, and IL-18 levels were inhibited by HGF treatment. There are signiﬁcant diﬀerences
between saline- and HGF-treated septic groups (24 hours after challenge, ANOVA test). (b) Attenuations of histological lesions, such as
hepatic degeneration, lung edema, and renal congestion by HGF in LPS-treated mice. (c) Prevention of hepatic, pulmonary and renal
dysfunctions by HGF in septic mice. ALT: alanine aminotransferase. BUN: blood urea nitrogen. There are signiﬁcant diﬀerences between
saline- and HGF-treated septic groups (24 hours after challenge, ANOVA test). (d) Improved survival rate within 4 days after HGF treatment
(n = 8 per group), with a signiﬁcant diﬀerence (96 hours, Kaplan-Meier test). Overall, recombinant HGF was shown to prohibit septic MOF
in a mouse model of sepsis [28, 29].
pathologicalsituations,includingsepsis.LPS-treatedrodents
are widely used as an animal model of septic ARDS.
Using this characterized model, we provide evidence that
early administration of HGF may be useful for inhibition
of septic ARDS [29]. In the saline-treated control group,
neutrophil inﬁltration, edematous lesion and ﬁbrin clotting
were observed in the lung post-LPS challenge. In contrast,
recombinant HGF strongly suppressed the onset of ARDS-
like histological lesions seen in the LPS-treated mice. Within
24 hours post-LPS challenge, control mice suﬀered from the
respiratory dysfunction with systemic cyanosis, resulting in
a 40%-survival within 3 days. Of note, HGF administration
blocked these clinical abnormalities [29]. As a result, more
than 80% of septic mice were rescued by recombinant HGF
treatments (Figure 2). Thus, HGF was shown to inhibit
septic ARDS in mice via both anti-inﬂammatory and anti-
coagulant pathways.
4.3. Inhibitory Eﬀects of HGF Administrations on Septic ARF.
ARF secondary to sepsis is a highly prevalent diagnosis
in the ICU setting and continues to be associated with a
high rate of morbidity (70%) [3]. The pathophysiology of
septic ARF involves ischemic or toxic injury to the renal
tubular epithelia, resulting in necrosis or apoptosis, and
clinically is characterized as acute tubular necrosis. LPS-
treated mice mimic the renal damage of human patients
during sepsis. We ﬁrst demonstrated that recombinantGastroenterology Research and Practice 7
Table 3: Landmark studies to demonstrate the therapeutic eﬀect of HGF on sepsis-related MOF in animal models.
Target disease Animal
model Dose and routes Outocomes References
Liver:
Septic fulminant hepatitis LPS + GalN
(mouse) rh-HGF 3mg/kg/d, ip
Inhibition of hepatic failure,
anti-apoptosis,
improved survival
Kosai et al. [40]
Septic fulminant hepatitis LPS + GalN
(rat) Adeno-HGF, ip Improved survival,
anti-apoptosis, hepatoprotection Nomi et al. [64]
Septic hepatitis LPS (mouse) rh-HGF 1mg/kg, sc
Anti-apoptosis,
HO-1 induction, IL-10 upregulation,
IL-6 downregulation
Kamimoto et al. [28]
Septic hepatitis LPS (rat) HGF-producing
cell implantation Anti-coagulation, hepatoprotection Seto et al. [44]
Kaido et al. [65]
Septic hepatitis LPS (rat) rh-HGF 1mg/kg, iv Hepatocyte replication Gao et al. [66]
Septic hepatitis CPL (rat) rh-HGF 1mg/kg, iv Improved survival,
anti-coagulation, hepatoprotection Kondo et al. [45]
Kidney:
Septic ARF LPS (mouse) rh-HGF 1mg/kg, sc
Improved survival,
inhibition of ARF, reduced tubular injury,
HO-1 induction
Kamimoto et al. [29]
Albuminuria LPS (mouse) rh-HGF 1mg/kg, sc
Anti-inﬂammation,
reduced albuminuria,
nephrin preservation, podocyte
protection
Kato et al. [56]
Lung:
Septic ARDS LPS (mouse) rh-HGF 1mg/kg, sc
Suppressed edema,
reduced neutrophils, alveoloprotection,
HO-1 induction
Kamimoto et al. [29]
Acute lung injury LPS (mouse) rh-HGF 1mg/kg, iv Enhancement of alveolar cell replication Gao et al. [66]
GalN: D-galactosamine; rh-HGF: recombinant human HGF; Adeno-HGF: adenovirus vector carrying HGF cDNA; CPL: cecal ligation and puncture; sc,
subcutaneous injection; iv: intravenous injection; ip: intraperitoneal injection. For other abbreviations, see text.
HGF strongly inhibited the onset of ARF in mice post-
LPS challenge [29]. Actually, administration of recombinant
HGF prohibited the LPS-mediated renal damages (such
as neutrophil inﬁltration, tubular damage, and glomerular
ﬁbrin deposition), especially within 24 hours post-LPS
challenge [29]. Consistent with the histological ﬁndings,
HGF was shown to improve the renal dysfunction of LPS-
challengedmice.ThisexperimentalresultindicatesthatHGF
supplement therapy might be available for inhibiting not
only ARDS but also septic ARF, an important lethal factor
of sepsis-induced MOF [3, 4].
4.4. Suppression of MOF by HGF in a Model of Polybacterial
Sepsis. In the clinical bedsides of ICU, MOF occurs through
a polybacterial infection. Thus, it is important to reevaluate
the eﬀect of HGF under pathological situations that mimic
the clinical setting. Polybacterial MOF is inducible in
animals by cecal ligation and puncture (CLP). Using CLP-
treated rats as a model of septic peritonitis, Kondo et al.
demonstrated the therapeutic eﬃcacy of recombinant HGF,
especially for attenuation of MOF. After the surgery of CPL,
hepatic degeneration became evident in rats, along with
leukocyte inﬁltration [45]. In contrast, recombinant HGF
inhibited CLP-associated hepatitis in rats. In this process,
HGF prevented the sepsis-induced loss of thrombomodulin,
a key endothelial molecule that counteracts DIC formation.
As a result, HGF supplement therapy improved the survival
rate of rats under persistent peritonitis with poly-bacterial
infections [45]. There is now ample evidence to show the
protective eﬀects of HGF during experimental sepsis in
animal models (Table 3).
4.5. Safety Evaluations of HGF in Experimental Animals. It is
important to discuss the possible side eﬀects of HGF during
septic conditions. Given that HGF produces anti-thrombotic
eﬀects via the upregulation of uPA [38], side eﬀects, such as
hemorrhage, may be alarmed. However, recombinant HGF
improved the LPS-induced prolongation of prothrombin
time in mice, with no signs of hemorrhage. Indeed, HGF
did not shorten the prothrombin time below normal levels,
as reported in the cirrhotic rodents [36]. Administrations
of recombinant HGF into normal rats for 4 weeks did not
modify the basal coagulation activity (data not shown),
suggesting little eﬀect of HGF on hemorrhage induction,
but careful attentions should be paid to this issue for future
clinical studies of HGF.8 Gastroenterology Research and Practice
We further discuss the consequence of HGF-mediated
suppression of inﬂammation during systemic infections. Of
note,HGFpreventsorganinjuriesinratswithsystemicinfec-
tion [45]. In the same CLP-treated model, HGF decreased
the number of bacteria in blood, and as a result, SIRS was
attenuated (unpublished data), implying other mechanisms
of HGF for the possible enhancement of bacterial clearance,
or for bacterial growth arrest. Thus, careful evaluation must
be done to clarify the possible inhibitory eﬀect of HGF on
bacteremia in septic patients.
Whether HGF is procarcinogenic or not should also be
discussed. Toxicological studies revealed that a daily intra-
venous injection of recombinant HGF for 4 weeks (i.e., 28
times) did not elicit tumor formation in rats or monkeys
(unpublished data). Given that a duration period of intra-
venous HGF treatment during acute infection is probably
within 7 days, we predict that the short-term injection of
HGF will not increase a cancer risk, and clinical trials (Phase
I) are now in progress with a careful focus on this issue. On
the other hand, tumor stroma-derived HGF plays a central
role in the invasion of cancer cells in growing tumors [10].
Thus, clinical use of HGF is contraindicated for patients who
have already manifested growing tumors.
Upregulation of endogenous HGF is required for min-
imizing tissue injuries at least in rodents [10], while blood
levels of HGF are increased in patients [16, 47, 48], thus
suggesting a possible contribution of HGF upregulation to
reducingsepticdamages.However,productionlevelsofHGF
seem insuﬃcient in septic rats, with a time lag between the
injury and HGF upregulation [19, 63]. Thus, HGF may be a
candidate for the therapeutic development of septic diseases
(Table 3), and large clinical studies are necessary to under-
stand the regulation of HGF in humans before proposing
HGF as a new drug target in such a complex system as sepsis.
5.MolecularMechanismsof
HGF-InducedAnti-Inﬂammation
TLR-mediated innate immune system triggers the onset
of MOF during infectious diseases. In particular, cytokine
storm, characterized by a dramatic increase in blood proin-
ﬂammatory cytokines, is a fundamental event that provokes
systemic coagulation and inﬂammation [67]. For example,
TNF-α and IL-6 are known to be critical for inducing
thrombosis in vascular vessels and necrosis/apoptosis in
parenchymal epithelium. Chemokines, including IL-8, and
adhesion molecules, such as ICAM-1, are also important
for the rolling and extravasation of leukocytes between
endothelial cells. These molecules are upregulated through
a common transcriptional factor, NF-κB[ 67]. We and other
groups have revealed a novel function of HGF for suppress-
ing NF-κBa c t i v a t i o ni nn u m e r o u st y p e so fc e l l s[ 32, 41–43].
This section describes the molecular mechanisms whereby
cytokine storm is attenuated by HGF, mainly focusing on
c-Met-downstream pathways leading to inhibition of TLR4-
mediated NF-κB activation.
5.1. Prevention of SIRS by HGF through an HO-1 Pathway
in Macrophages. Given that cytokine storm is responsible
for coagulation and inﬂammation during sepsis, therapeutic
eﬀectof recombinant HGF may be due to the possible down-
regulation of proinﬂammatory cytokines. Using LPS-treated
mice, we found that c-Met levels increased in hepatic and
pulmonary macrophages, a major contributor to cytokine
storm [28, 29]. Of note, recombinant HGF targeted these
macrophages at the early stage of SIRS and strongly blocked
the LPS-mediated increases in blood IL-1β, IL-6, and IL-18
in septic mice [28, 29, 56].
Hemeoxygenase-1 (HO-1) is the rate-limiting enzyme
fortheoxidativedegradationofhemeintocarbonmonoxide,
free iron, and biliverdin [68] .T h e s ep r o d u c t sp l a yp i v o t a l
roles in the attenuations of cytokine storm through NF-κB
inactivation, especially during sepsis [68]. In HO-1-deﬁcient
mice, blood IL-6 levels dramatically increased (>100-fold of
wild-type) after the LPS injection [69], thereby identifying
HO-1asanessentialsuppressorofcytokine storm.Wefound
that recombinant HGF enhanced LPS-mediated expression
of HO-1 by the hepatic and pulmonary macrophages in
septic mice, and was associated with decreases in blood IL-
1β, IL-6, and IL-18 levels [28, 29]. Such an HGF-induced
attenuation of cytokine storm was partially restored by an
HO-1 inhibitory treatment [29]. As a result, LPS-mediated
NF-κBactivationinresidentandinﬁltratedmacrophageswas
suppressed by HGF treatment.
Taken together, we predict that enhancement of HO-1 by
HGF in macrophage is, in part, involved in the counteractive
eﬀectofHGFonTLR4-mediatedinﬂammation.Theincrease
in HO-1 by HGF in the presence of LPS is due to a
posttranscriptional pathway (i.e., stabilization of HO-1),
while HGF may increase HO-1 in septic organs via a
transcriptional pathway. Thus, both pathways are important
for HGF-mediated protection during sepsis (Figure 3(a)).
5.2. Counteractive Eﬀect of HGF on TLR4-Mediated Inﬂam-
matory Signaling. We emphasized the involvement of HO-1
in HGF-mediated anti-inﬂammation, but its contribution is
partial, especially in vitro [28], suggesting a direct inhibitory
eﬀectofHGFontheLPS-TLR4signalingpathway.Activation
of GSK3β is known to be required for promoting TLR4-
mediated NF-κB activation. Recently, Coudriet et al. pro-
vided evidence that inhibition of GSK3β activity by HGF
leads to the inhibitory outcome of TLR4-mediated NF-κB
activation, as follows [46]. In a culture of bone marrow-
derived macrophage, LPS caused a nuclear shift of NF-κB
(p55–p65 dimer), phosphorylation of p65 at serine-276, and
then proinﬂammatory cytokines, such as IL-6, were over-
produced. In this pathway, CREB-binding protein (CBP) is
essential for NF-κB activation as a coactivator that directly
interacts with p65/NF-κB[ 46]. In contrast, HGF elicited
the phosphorylation of PI3K and AKT pathways at a c-Met
downstream, and, more importantly, GSK3β activity was
attenuated by HGF-mediated phospho-AKT. Consistently,
NF-κB activation (i.e., nuclear localization and p65 serine-
276 phosphorylation) after LPS challenge was prohibited by
HGF. In this process, c-Met signaling inhibited the binding
of CBP to NF-κB through enhancing a direct interaction
between phospho-CREB and CBP. Under the HGF-mediated
loss of NF-κB-CBP complex, the transcription of IL-6 wasGastroenterology Research and Practice 9
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Figure 3: Molecular mechanisms of HGF-c-Met-mediated signaling for inhibiting TLR4-mediated NF-κB activation in macrophages. (a)
HO-1-dependent pathway. HO-1 is upregulated at a downstream of TLR4 through the activation of transcriptional factors, such as Nrf2 or
HIF-1. During heme metabolism by HO-1, carbon monoxide (CO), free iron and biliverdin are generated, and these products attenuate NF-
κBactivation(i.e.,negativefeedbacksystem).Inthisprocess,c-MetsignalenhancestheHO-1transcriptionalpathway(1a)orstabilizesHO-1
from degradation (1b). Overall, HGF-mediated increases in HO-1 partially contribute to NF-κB inactivation (1c). (b) GSK3β-inactivated
pathway. LPS-TLR4-mediated signaling leads to nuclear localization and activation of NF-κBv i aG S K 3 β activation pathway. In contrast,
HGF-c-Met signaling elicits PI3K and AKT phosphorylation, and then GSK3β is inactivated. As a result, CBP, a coactivator of NF-κB, is
sequestered from the p65 subunit of NF-κB, and transcription of inﬂammatory molecules, such as TNF-α, IL-6 and ICAM-1, is arrested.
arrested, even in the presence of LPS (Figure 3(b)). Such a
direct eﬀect of HGF on TLR-4 downstream is also important
to explain the mechanisms whereby HGF inhibits cytokine
storm.
5.3. Inhibition of Cytokine-Mediated NF-κBA c t i v a t i o nb y
HGF in Various Cells. We further discuss the suppressive
eﬀect of HGF on NF-κB activation under pathological
conditions. TNF-α is known to elicit NF-κB activation,
resulting in acceleration of MOF. When HGF is added into
human endothelial cells in the presence of TNF-α,N F - κB
activation becomes faint in an HGF-dependent manner [32,
34]. As a result, inductions of ICAM-1 and E-selectin and
leukocyte attachments are suppressed by HGF, contributing
to an HGF-mediated improvement in kidney diseases in
rodents [32, 33]. In this process, HGF rapidly activates nitric
oxide production in cultured endothelial cells via inducing
nitric oxide synthase (NOS), and this is associated with
the decrease in E-selectin [34]. Notably, HGF-mediated NF-
κB inactivation and E-selectin downregulation are abolished
by NOS-inhibitors [34]. Thus, the NO-dependent pathway
maybe involved in the counteractive eﬀect of HGF on TNF-
α-inducedNF-κBactivation.HGFinhibitsvascularendothe-
lial growth factor- (VEGF-) induced NF-κBa c t i v a t i o n[ 70].
These results indicate that HGF can attenuate further tissue
inﬂammation and injury, even if cytokine storm occurs in
the middle and late stages of septic diseases.
5.4. Other Mechanisms Involved in HGF-Induced Anti-
Inﬂammation. We ﬁnally discuss other mechanisms of
HGF-mediated anti-inﬂammatory eﬀects. IL-10 is an anti-
inﬂammatory cytokine: LPS-induced hepatitis is more
evident in IL-10-knokout mice than in wild-type mice
[71]. HGF promotes IL-10 production in LPS-stimulated
macrophages via an HO-1-dependent pathway [28]. HGF-
mediated enhancement of phospho-CREB-CBP interaction,
as mentioned above, may participate in the IL-10 neo-
induction [46]. Furthermore, HGF stimulates secretion
of IL-1-receptor antagonist that can inhibit inﬂammatory
events [72]. Monocyte chemoattractant protein-1 (MCP-1)
is critical for recruiting macrophages, while HGF inhibits
the MCP-1 expression in vivo [73]a n din vitro [74]. These
biological activities may also contribute to HGF-induced
anti-inﬂammatory outcomes during sepsis.10 Gastroenterology Research and Practice
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Figure 4: Step-by-step therapy using HGF in a chronology of septic phases including infection, SIRS, coagulation, and MOF. HGF inhibits
the development of sepsis-induced MOF through diﬀerent ways at diﬀerent phases. (a) In an initial step, HGF targets endotoxin-primed
macrophages and inhibits cytokine storm via indirect (i.e., HO-1 recruitment) and direct (i.e., GSK3β inactivation) pathways [29, 46]; (b)
in an early step (i.e., post-cytokine storm), HGF protects endothelial cells from cytokine-induced inﬂammatory events, such as ICAM-1 and
E-selectin overexpressions [32–34], and HGF also prevents DIC via the preservation of thrombomodulin on endothelial cells [44, 45]; (c)
in a middle step (i.e., after coagulation), HGF protects resident functional cells from hypoxia or cytokines via early induction of Bcl-xL or
Bcl-2 [40]; ﬁnally (d) in an advanced stage (i.e., after injury), HGF enhances tissue repair via enhancing mitogenesis and morphogenesis of
surviving epithelial cells [10, 15].
6.SummaryandPerspective
This paper summarized new insights into HGF-mediated
anti-inﬂammatory mechanisms during diseases, including
sepsis. On the other hand, decoy oligonucleotides against
NF-κB are known to inhibit NF-κB-dependent gene tran-
scription by competing with cis-acting elements of inﬂam-
matory genes [75]. Several investigators have postulated the
usefulness of “NF-κB decoy” in various types of inﬂam-
matory diseases, including sepsis [76, 77]; however, its
eﬀect is limited to anti-inﬂammation. In addition to this
eﬀect [32, 41–43], HGF has numerous merits, such as anti-
coagulation in endothelial cells, anti-apoptosis and regen-
eration in epithelial cells, and these eﬀects may reduce the
septic injury in each stage (Figure 4). Results obtained from
animal studies suggest that HGF might be an interesting and
therapeutic option.
Given that growth factors have various biological activi-
ties, growth factor therapy is still hopeful for treating sepsis;
however, VEGF often elicits inﬂammation via activating NF-
κB pathways, as reported elsewhere [70]. Other growth fac-
tors, such as IGF-1 and HB-EGF, also enhance inﬂammation
and apoptosis [78, 79]. HGF has beneﬁcial eﬀects opposite
to these growth factors [32, 70]. Since the HGF activation
system may be impaired during sepsis [80], intravenous
injection of an active form of HGF (i.e., recombinant HGF)
could be the primary choice for HGF supplemental therapy.
Furthermore, transplantation of HGF-producing cells (e.g.,
HGF cDNA-transfected stromal cells [44]) may also be
applicable at a sub-acute phase, although it will take several
days for the cell preparation. Such a cell-speciﬁc HGF
delivery system may reduce a hemodynamic eﬀect of HGF,
such as mild hypotension [81].
HGF may be present in a form of inactive precursor in
blood [62] .T h u s ,H G Fa c t i v a t o r s ,s u c ha su P A ,m a ya l s ob e
available for enhancing the eﬀects of HGF. Supplementation
of active HGF, as well as the enhancement of HGF activation,
might be a new option for reducing MOF, and future clinical
studies would shed more light on this hypothesis. Current
clinical studies, focusing on the safety and eﬀectiveness of
HGF, have been tested in patients with various diseases
worldwide [82–85]. HGF is now much more than a growth
factor [86–88], and further basic and clinical studies using
HGF will provide new insights into cell signaling networks
connected to an attenuation of innate immune systems
during inﬂammatory diseases, including sepsis.
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